You are here > News and publications

News and publications

Promethera Biosciences opens the French part of its phase I/II clinical trial in cell therapy

27/02/2013

Promethera successfully administers Promethera® HepaStem in an adolescent suffering from an Urea Cycle Disorder at Hôpital Jeanne de Flandre (Lille, France)

 

Mont-Saint-Guibert (Belgium) - February 27, 2013 – Promethera Biosciences, a Belgian biotechnology company developing Promethera®HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial. The intervention was performed in January 2013 at the University Children’s Hospital Jeanne de Flandre in Lille (France). 

 

 

Download this file (EN)

 

Télécharger ce fichier (FR)

Contacts

PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
B-1435 Mont-Saint-Guibert
(Belgium)
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01

News and Public release

CEO John Tchelingerian to Discuss Strategic Collobarations and Partnering Strategies in Cell Therapy at ARM’s Advanced Therapies Summit
Collaboration to Drive Development and Commercialization of Promethera’s Cell-based Liver-Focused Therapeutics Portfolio in Korea